Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria, tetanus, pertussis (whole cell), hepatitis B (rDNA) vaccine (adsorbed)
- Development stage
- Unknown
- Lead developer
- Bharat Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Comvac 4 (also known as Comvac 4 HB or COMVAC 4-Hb) is a tetravalent combination vaccine developed and manufactured by Bharat Biotech. It is designed for the active immunization of infants and young children against diphtheria, tetanus, pertussis (whooping cough), and hepatitis B. The vaccine is formulated as a uniform suspension containing diphtheria toxoid, tetanus toxoid, inactivated whole-cell Bordetella pertussis, and recombinant hepatitis B surface antigen (HBsAg) adsorbed on an aluminum hydroxide adjuvant. It is administered intramuscularly, typically in a three-dose primary series, to stimulate the production of protective antibodies against these four pathogens.
- Brand names
- COMVAC 4-HbCOMVAC4-HbCOMVAC-4-HbComvac 4Comvac4Comvac-4Comvac 4 HBComvac4 HBComvac-4 HB
- Other names
- DTP-HBV vaccineDTP-HepB vaccineDTwP-HepB vaccinediphtheria, tetanus, pertussis, and hepatitis B vaccine
02
Targets
HBsAg (Hepatitis B surface antigen)Diphtheria toxin
Beyond the preview
Go deeper on diphtheria, tetanus, pertussis (whole cell), hepatitis B (rDNA) vaccine (adsorbed).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria, tetanus, pertussis (whole cell), hepatitis B (rDNA) vaccine (adsorbed).